GHRP-6 and L-dopa stimulate growth hormone release through fundamentally different neuroendocrine pathways. GHRP-6 acts directly on the ghrelin receptor (GHSR-1a) on somatotrophs, producing acute GH release. L-dopa increases dopamine levels, which modulate GH release through hypothalamic GHRH and somatostatin regulation. Their comparison illustrates the distinction between direct pituitary stimulation and hypothalamic modulation.
- Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids)
- Modifications: D-amino acids at positions 2 and 5, C-terminal amidation
- MW: 873 Da
- Charge at pH 7.4: +2
- Receptor: GHSR-1a (ghrelin receptor) — Gαq coupled
- Half-life: 15–30 minutes (serum)
- Bioavailability: <5% oral; ~100% SC/IV
- FDA status: Not approved; research chemical
- Chemical name: 3,4-dihydroxy-L-phenylalanine
- Structure: Amino acid (dopamine precursor)
- MW: 197 Da
- Charge at pH 7.4: 0 (zwitterionic)
- Receptor: None directly (converted to dopamine)
- Half-life: 1–2 hours (serum)
- Bioavailability: ~30% oral (with carbidopa)
- FDA-approved indications: Parkinson’s disease, restless legs syndrome
- GHSR-1a binding: Direct agonist at ghrelin receptor on somatotrophs
- Gαq activation: Phospholipase C (PLC) stimulation
- IP₃ + DAG generation: Dual second messenger system
- Ca²⁺ mobilization: IP₃-mediated ER Ca²⁺ release
- PKC activation: DAG-dependent protein kinase C
- Voltage-gated Ca²⁺ channels: Membrane depolarization
- GH vesicle exocytosis: Direct pituitary stimulation
Additional GHSR-1a effects:
- ↑Appetite (hypothalamic GHSR)
- ↑Cortisol (adrenal GHSR)
- ↑ACTH (pituitary GHSR)
- ↑Prolactin (pituitary GHSR)
- L-DOPA absorption: Oral GI absorption
- Decarboxylation: AADC (aromatic L-amino acid decarboxylase) → dopamine
- CNS penetration: Dopamine crosses blood-brain barrier
- Hypothalamic effects: Dopamine modulates GHRH and somatostatin
Dopamine-GH pathway:
- Low dopamine: ↑GHRH release, ↑GH
- High dopamine: ↑Somatostatin release, ↓GH
- Net effect: Dose-dependent, biphasic
- Context-dependent: Stress, sleep, exercise modify response
Additional L-dopa effects:
- ↑Dopamine in basal ganglia (Parkinson’s)
- ↑Norepinephrine and epinephrine
- ↓Prolactin (dopamine-mediated)
- ↑Cardiac output
- ↑Blood pressure
| Parameter | GHRP-6 | L-DOPA |
|---|
| Peak GH (above baseline) | 15–30 ng/mL | 5–15 ng/mL |
| Time to peak | 15–30 minutes | 60–90 minutes |
| Duration of GH release | 2–4 hours | 4–6 hours |
| Dose-response relationship | Linear (within range) | Biphasic (low ↑, high ↓) |
| Reproducibility | High | Moderate |
| Suppression by somatostatin | Partial | Complete |
| Parameter | GHRP-6 | L-DOPA |
|---|
| Mechanism | Direct GHSR agonist | Indirect (dopamine modulation) |
| Site of action | Somatotroph (direct) | Hypothalamus (indirect) |
| GH pulsatility | Mimics natural pulse | Disrupts natural pattern |
| IGF-1 increase | 20–40% | 10–20% |
| Appetite stimulation | Strong | Minimal |
| Cortisol elevation | Significant | Minimal |
| Prolactin effect | ↑ | ↓ |
| Indication | Dose | Route | Evidence |
|---|
| GH stimulation testing | 1 µg/kg | IV/SC | Moderate |
| GH deficiency (diagnostic) | 1 µg/kg | IV | Investigational |
| Appetite stimulation | 100–300 µg | SC | Limited |
| Research | Variable | Various | Preclinical |
| Indication | Dose | Route | Evidence |
|---|
| Parkinson’s disease | 300–1200 mg/day (with carbidopa) | Oral | Strong (approved) |
| Restless legs syndrome | 100–600 mg/day | Oral | Moderate (approved) |
| GH stimulation testing | 500 mg | Oral | Moderate |
| Hyperprolactinemia | 500 mg | Oral | Limited |
| Adverse Effect | Frequency | Severity | Mechanism |
|---|
| Increased appetite | 80–90% | Expected | Hypothalamic GHSR |
| Flushing | 20–30% | Mild | Vasodilation |
| Hunger pangs | 30–50% | Moderate | Hypothalamic |
| Cortisol elevation | 20–30% | Moderate | Adrenal GHSR |
| Prolactin increase | 10–20% | Mild | Pituitary GHSR |
| Dizziness | 10–15% | Mild | Vasodilation |
| GI discomfort | 5–10% | Mild | Unknown |
| Adverse Effect | Frequency | Severity | Mechanism |
|---|
| Nausea | 30–50% | Moderate | Peripheral dopamine |
| Orthostatic hypotension | 20–30% | Moderate | Dopamine-mediated |
| Dyskinesia (long-term) | 30–50% | Moderate | Basal ganglia adaptation |
| Hallucinations | 10–20% | Moderate | CNS dopamine |
| Impulse control | 5–15% | Moderate | Mesolimbic dopamine |
| Anxiety | 10–20% | Mild | CNS dopamine |
| Insomnia | 10–15% | Mild | Arousal |
| Interacting Agent | Effect | Severity |
|---|
| Somatostatin analogues | ↓GH response | Moderate |
| Glucocorticoids | ↓GH response | Minor |
| Dopamine agonists | ↑GH release | Minor |
| Insulin | Hypoglycemia risk | Moderate |
| Interacting Agent | Effect | Severity |
|---|
| MAO inhibitors | Hypertensive crisis | Major |
| COMT inhibitors | ↑L-DOPA levels | Moderate |
| Antipsychotics | ↓L-DOPA efficacy | Major |
| Metoclopramide | ↓L-DOPA absorption | Moderate |
| Iron supplements | ↓L-DOPA absorption | Moderate |
| Pyridoxine (without carbidopa) | ↓L-DOPA bioavailability | Moderate |
GHRP-6 and L-dopa stimulate GH through fundamentally different pathways. GHRP-6 directly activates GHSR-1a on somatotrophs, producing rapid, reproducible GH release with high appetite stimulation and cortisol elevation. L-dopa increases dopamine, modulating hypothalamic GHRH/somatostatin balance to influence GH indirectly. GHRP-6 produces higher peak GH but with appetite stimulation as a limiting side effect. L-dopa produces lower GH stimulation but with additional benefits (↓prolactin, Parkinson’s treatment). GHRP-6 is more useful for GH stimulation testing and research; L-dopa has established clinical indications in Parkinson’s disease.
